株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

チェックポイント阻害剤:世界市場

Checkpoint Inhibitors: Global Markets

発行 BCC Research 商品コード 726421
出版日 ページ情報 英文 141 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.83円で換算しております。
チェックポイント阻害剤:世界市場 Checkpoint Inhibitors: Global Markets
出版日: 2018年10月12日 ページ情報: 英文 141 Pages
担当者のコメント
2018年度ノーベル賞を受賞し、オプジーボ薬剤でがん治療薬開発において注目を集める免疫チェックポイント阻害剤に着目した市場レポートが米国BCC Researchよりリリースされました。PD-1/PD-L1 、CTLA-4、IDO-1、LAG-3、TIM-1,3、CD47/SIRPアルファ等、各種開発トレンドの詳細パイプライン、参画企業プロファイルをまとめており、現時点での最新トレンドを入手いただけるレポートです。
概要

世界におけるチェックポイント阻害剤の市場規模は、2018年から2023年にかけて14.4%のCAGR (年間複合成長率) で推移し、2018年の149億米ドルから2023年までに293億米ドルへ拡大すると予測されています。

当レポートでは、世界におけるチェックポイント阻害剤市場について分析し、世界市場の概要、世界市場動向の分析と予測、市場情勢・革新的な戦略・アンメットメディカルニーズについての議論、バイオマーカー開発・免疫修飾・革新的なデリバリー技術・将来の情勢に関する情報、各阻害薬についての市場分析、および主要企業の包括的なプロファイルなどを提供しています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 癌免疫市場・チェックポイント市場統計

  • 癌免疫
  • アンメットメディカルニーズ
  • 革新的な戦略
  • 新しい標的アプローチ
  • 現在の市場情勢

第4章 PD-1/PD-L1 阻害薬

  • イントロダクション
  • 市販薬
  • Nivolumab (Opdivo), BMS
  • Atezolizumab (Tecentriq), Genentech
  • Avelumab (Bavencio), Merck KGaA/Pfizer
  • Durvalumab (Imfinzi), AstraZeneca
  • 臨床プログラム:フェーズ3
  • 臨床プログラム:フェーズ2
  • 臨床プログラム:フェーズ1
  • 前臨床プログラム
  • 市場予測

第5章 CTLA-4

  • イントロダクション
  • 市販薬
  • 臨床プログラム:フェーズ3
  • 臨床プログラム:フェーズ1/2
  • 臨床プログラム:フェーズ1
  • 市場予測

第6章 IDO-1

  • イントロダクション
  • IDO-1
  • 臨床プログラム:フェーズ3
  • 臨床プログラム:フェーズ1
  • 前臨床プログラム
  • 市場予測

第7章 LAG-3

  • イントロダクション
  • LAG-3
  • 臨床プログラム:フェーズ2/3
  • 臨床プログラム:フェーズ2
  • 前臨床プログラム
  • 市場予測

第8章 TIM-1,3

  • イントロダクション
  • TIM-1,3
  • 臨床プログラム:フェーズ2
  • 臨床プログラム:フェーズ1/2
  • 臨床プログラム:フェーズ1
  • 前臨床プログラム
  • 市場予測

第9章 CD47/SIRPアルファ

  • イントロダクション
  • CD47/SIRPアルファ
  • 臨床プログラム:フェーズ1/2
  • 臨床プログラム:フェーズ1
  • 前臨床プログラム
  • 市場予測

第10章 企業プロファイル

第11章 付録A:略語リスト

第12章 付録B:用語

第13章 付録C:参考資料

図表

List of Tables

  • Summary Table: Global Market for Checkpoint Inhibitors, by Drug Class, Through 2023
    • Table 1: Adverse Events Associated with Immune-Checkpoint Blockade
    • Table 2: Global Market for Marketed Checkpoint Inhibitors, by Drug Target, Through 2023
    • Table 3: Global Market for Developmental Checkpoint Inhibitors, by Drug Target, Through 2023
    • Table 4: Comparison of PD-L1-PD-L2 ligands
    • Table 5: Summary of Anti-PD-1/PD-L1 Therapies Approved Indications
    • Table 6: PD-1/PD-L1 Agents in Development
    • Table 7: Pembrolizumab Approved Indications
    • Table 8: Global Market for Pembrolizumab, by Region, Through 2023
    • Table 9: Global Market for Pembrolizumab, by Indication, Through 2023
    • Table 10: Nivolumab Approved Indications
    • Table 11: Global Market for Nivolumab, by Region, Through 2023
    • Table 12: Global Market for Nivolumab, by Indication, Through 2023
    • Table 13: Atezolizumab Approved Indications
    • Table 14: Global Market for Atezolizumab, by Region, Through 2023
    • Table 15: Global Market for Atezolizumab, by Indication, Through 2023
    • Table 16: Avelumab Approved Indications
    • Table 17: Global Market for Avelumab, by Region, Through 2023
    • Table 18: Global Market for Avelumab, by Indication, Through 2023
    • Table 19: Durvalumab Approved Indications
    • Table 20: Global Market for Durvalumab, by Region, Through 2023
    • Table 21: Global Market for Duvalumab, by Indication, Through 2023
    • Table 22: Regeneron's NSCLC Development Program
    • Table 23: Global Market for Cemiplimab, by Region, Through 2023
    • Table 24: Global Market for Cemiplimab, by Indication, Through 2023
    • Table 25: Clinical Trials Evaluating Tislelizumab
    • Table 26: Clinical Trials Evaluating INCMGA00012
    • Table 27: Global Market for anti-PD-1/PD-L1 Therapies, by Product, Through 2023
    • Table 28: CTLA-4 Agents in Development
    • Table 29: Global Market for Anti-CTLA-4 Therapies, by Product, Through 2023
    • Table 30: Summary of Anti-IDO-1 Developmental Programs
    • Table 31: Clinical Trials Evaluating Epacadostat
    • Table 32: Clinical Trials Evaluating Navoximod (GDC-0919)
    • Table 33: Global Market for anti-IDO-1 Therapies, by Product, Through 2023
    • Table 34: Anti- LAG-3 Therapies in Development
    • Table 35: Clinical Trials Evaluating Relatlimab
    • Table 36: Clinical Trials Evaluating LAG525
    • Table 37: Clinical Trials Evaluating IMP321
    • Table 38: Clinical Trials Evaluating BI 754111
    • Table 39: Clinical Trials Evaluating FS118
    • Table 40: Clinical Trials Evaluating Sym022
    • Table 41: Clinical Trials Evaluating TSR-033
    • Table 42: Global Market for anti-LAG-3 Therapies, by Product, Through 2023
    • Table 43: TIM-1,3 Agents in Development
    • Table 44: Global Market for Anti-TIM-1,3 Therapies, by Product, Through 2023
    • Table 45: T-Cell and Macrophages Characteristics
    • Table 46: Clinical Trials Evaluating CD47-SIRPα Targeted Therapies
    • Table 47: Clinical Trials Evaluating 5F9
    • Table 48: Clinical Trials Evaluating ALX148
    • Table 49: Clinical Trials Evaluating C-9002
    • Table 50: Clinical Trials Evaluating C-9002
    • Table 51: Clinical Trials Evaluating TTI-621
    • Table 52: Clinical Trials Evaluating TTI-622
    • Table 53: Global Market for anti-CD47-SIRPα Therapies, by Product, Through 2023
    • Table 54: Abbreviations Used in Checkpoint Inhibitors
    • Table 55: Glossary of Terms
    • Table 56: Checkpoint Inhibitors Sources
    • Table 57: Chapter 2 Sources
    • Table 58: Chapter 3 Sources
    • Table 59: Chapter 4 Sources
    • Table 60: Chapter 5 Sources
    • Table 61: Chapter 6 Sources
    • Table 62: Chapter 7 Sources
    • Table 63: Chapter 8 Sources

List of Figures

  • Summary Figure: Global Market for Checkpoint Inhibitors, by Drug Class, 2017-2023
    • Figure 1: Potential Targets for Checkpoint Inhibition in Clinical Evaluation
    • Figure 2: Global Market for Marketed Checkpoint Inhibitors, by Drug Target, 2017-2023
    • Figure 3: Global Market for Developmental Checkpoint Inhibitors, by Drug Target, 2017-2023
    • Figure 4: Pembrolizumab Comprehensive Clinical Trial Programs, by Status
    • Figure 5: Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy
    • Figure 6: Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type
    • Figure 7: Global Market for Pembrolizumab, by Region, 2017-2023
    • Figure 8: Nivolumab Comprehensive Clinical Trial Programs, by Status
    • Figure 9: Nivolumab Comprehensive Clinical Trial Programs, by Therapy
    • Figure 10: Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type
    • Figure 11: Global Market for Nivolumab, by Region, 2017-2023
    • Figure 12: Atezolizumab Comprehensive Clinical Trial Programs, by Status
    • Figure 13: Atezolizumab Comprehensive Clinical Trial Programs, by Therapy
    • Figure 14: Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type
    • Figure 15: Global Market for Atezolizumab, by Region, 2017-2023
    • Figure 16: Avelumab Comprehensive Clinical Trial Programs, by Status
    • Figure 17: Avelumab Comprehensive Clinical Trial Programs, by Therapy
    • Figure 18: Avelumab Comprehensive Clinical Trial Programs, by Cancer Type
    • Figure 19: Global Market for Avelumab, by Region, 2017-2023
    • Figure 20: Durvalumab Comprehensive Clinical Trial Programs, by Status
    • Figure 21: Durvalumab Comprehensive Clinical Trial Programs, by Therapy
    • Figure 22: Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type
    • Figure 23: Global Market for Durvalumab, by Region, 2017-2023
    • Figure 24: Global Market for Cemiplimab, by Region, 2017-2023
    • Figure 25: Global Market for anti-PD-1/PD-L1, by Product, 2017-2023
    • Figure 26: Signaling Molecules Involved in CD28 and CTLA-4 Function
    • Figure 27: Fab Fragment of ipilimumab (blue) Binding CTLA-4 (green)
    • Figure 28: Global Market for Anti-CTLA-4 Therapies, by Product, 2017-2023
    • Figure 29: Schematic of Mechanism of Action of IDO-1 Inhibition on Tryptophan (Trp) Catabolism in Cancer
    • Figure 30: Structure of Epacadostat
    • Figure 31: Structure of BMS-986205
    • Figure 32: Structure of A) Inoximod and B) navoximod
    • Figure 33: Global Market for anti-IDO-1 Therapies, by Product, 2017-2023
    • Figure 34: Global Market for Anti-LAG3 Therapies, by Product, 2017-2023
    • Figure 35: Schematic of Mechanism of Action of TIM-3 in T-Cell Activation and Synergistic Effect on PD-1 Inhibition
    • Figure 36: Global Market for Anti-TIM-1,3 Therapies, by Product, 2017-2023
    • Figure 37: Mechanism of Action of Anticd47/SIRPα Therapies
    • Figure 38: Structure of ALX148
    • Figure 39: Structure of TTI-621
    • Figure 40: Structure of TTI-622
    • Figure 41: Global Market for anti-CD47-SIRPα, by Product, 2017-2023
目次
Product Code: PHM185A

Report Highlights:

The global checkpoint inhibitors market should reach $29.3 billion by 2023 from $14.9 billion in 2018 at a compound annual growth rate (CAGR) of 14.4% for the period of 2018-2023.

The marketed checkpoint inhibitors market is expected to grow from $14.9 billion in 2018 to nearly $26.5 billion in 2023 at a CAGR of 12.1% for the period of 2018-2023.

The PD-1/PD-L1 segment of the marketed checkpoint inhibitors market is expected to grow from $13.5 billion in 2018 to $24.9 billion in 2023 at a CAGR of 13.0% for the period of 2018-2023.

Report Scope:

This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates that target PD-1/PD-L1, CTLA-4, IDO-1, LAG-3, TIM-3 and CD47/SIRPα. The report analyzes the market trends, key medical needs and provides insights into recent advances in the modulation of checkpoint inhibition in the treatment of cancer through the development of fully human monoclonal antibodies, bispecific antibodies, fusion proteins and Chimeric Antigen Receptor (CAR) T cells.

Report Includes:

  • 21 data tables and 43 additional tables
  • An overview of the global market for checkpoint inhibitors
  • Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Discussion of the market landscape and innovative strategies, and the areas of unmet medical needs
  • Information on the biomarker development, immune modulation, innovative delivery technologies, and the future landscape
  • Market analysis for CP inhibitors, including PD-1/PD-L1 agents, CTLA-4 agents, TIM-3 agents, LAG-3 agents, IDO-1 agents, and SIRPα agents
  • Comprehensive company profiles of major players in the industry, including Agenus, Inc., BeiGene, BIOCAD, Forty Seven, Inc., Seattle Genetics, Inc., Shanghai Cell Therapy, Tesaro, Inc. and Xencor

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Immuno-Oncology Market and Checkpoint Market Statistics

  • Immuno-Oncology
    • Co-Stimulatory Immune Checkpoint Targets
    • Inhibitory Immune Checkpoint Targets
    • Immunometabolic Modulatory Targets
  • Unmet Medical Needs
    • New Biomarkers to Stratify Patients
    • Relapse/Refractory Patients
    • Treatment Efficacy and Tolerability
  • Innovative Strategies
    • Emerging New Checkpoint Inhibitors
    • New Combinations
  • Novel Targeted Approaches
    • Humanized Monoclonal Antibodies
    • Bispecific Agents
    • CAR-T Cells
  • Current Market Landscape
    • Marketed Checkpoint Inhibitors
    • Developmental Checkpoint Inhibitors

Chapter 4: PD-1/PD-L1 Agents

  • Introduction
  • Marketed
    • Pembrolizumab (Keytruda), Merck & Co.
    • Companion Diagnostic
    • Clinical Trial Program
    • Pembrolizumab Forecasts
  • Nivolumab (Opdivo), BMS
    • Companion Diagnostic
    • Clinical Trial Program
    • Nivolumab Forecasts
  • Atezolizumab (Tecentriq), Genentech
    • Companion Diagnostic
    • Clinical Trial Program
    • Atezolizumab Forecasts
  • Avelumab (Bavencio), Merck KGaA/Pfizer
    • Companion Diagnostic
    • Clinical Trial Program
    • Avelumab Forecasts
  • Durvalumab (Imfinzi), AstraZeneca
    • Companion Diagnostic
    • Clinical Trial Program
    • Durvalumab Forecasts
    • Cemiplimab (Libtayo), Regeneron/Sanofi
  • Clinical Programs Phase 3
    • Spartalizumab, Novartis
    • Tislelizumab, BeiGene
  • Clinical Programs Phase 2
    • INCMGA0012, Incyte/MacroGenics
    • LY3300054, Eli Lilly
  • Clinical Programs Phase 1
    • BI 754091, Boehringer Ingelheim
    • CA-170, Curis/Aurigene
    • CS1001, CStone Pharmaceuticals
    • FS118, Merck KGaA/F-Star
  • Preclinical Programs
    • aCD27xaPD-L1, Celldex
    • MEDI1109, AstraZeneca
    • XmAb20717 and XmAb23104, Xencor
  • Market Forecasts

Chapter 5: CTLA-4

  • Introduction
  • Marketed Drugs
    • Yervoy (ipilimumab), BMS
  • Clinical Programs Phase 3
    • Tremelimumab, Astra Zeneca
  • Clinical Programs Phase 1/2
    • Anti-CTLA-4/PD-1 Expressing MUC1-CAR-T, Shanghai Cell Therapy
  • Clinical Programs Phase 1
    • AGEN-1884, Agenus
    • BCD-145, Biocad
    • CS1002, CStone Pharmaceuticals
    • REGN4659, Regeneron Pharmaceuticals
  • Market Forecasts

Chapter 6: IDO-1

  • Introduction
  • IDO-1 Developmental Therapies
  • Clinical Programs Phase 3
    • Epacadostat, Incyte
  • Clinical Programs Phase 1
    • BMS 986205, Bristol-Myers Squibb
    • EOS200271, iTeos Therapeutics
    • Indoximod (NLG-001) and Navoximod (NLG 919, GDC-0919, R6078), NewLink Genetics
    • KHK2455, Kyowa Kirin
    • LY3381916, Eli Lilly
  • Preclinical Programs
  • Market Forecasts

Chapter 7: LAG-3

  • Introduction
  • LAG-3 Developmental Therapies
  • Clinical Programs Phase 2/3
    • Relatlimab (BMS-986016), BMS
  • Clinical Programs Phase 2
    • LAG525 (IMP701), Novartis/Immuntep (Prima BioMed)
    • Eftilagimod Alpha (IMP321), Immuntep (Prima BioMed)
    • BI 754111, Boehringer Ingelheim
    • FS118, Merck KGgaA/ F-star
    • Sym022, Shire/Symphogen A/S
    • TSR-033, Tesaro/Anaptys Bio
    • XmAb22841, Xencor
  • Preclinical Programs
    • INCAGN02385, Incyte/Agenus
  • Market Forecasts

Chapter 8: TIM-1,3

  • Introduction
  • TIM-1,3 Developmental Therapies
  • Clinical Programs Phase 2
    • Bavituximab, Merck Sharp & Dohme/Oncologie International
  • Clinical Programs Phase 1/2
    • CDX-014, Celldex Therapeutics/Seattle Genetics
    • MGB453 +/- Spartalizumab, Novartis
  • Clinical Programs Phase 1
    • LY3321367 +/- LY3300054, Eli Lilly
    • TSR-022 +/- TSR-042, Tesaro/AnaptysBio
  • Preclinical Programs
    • CA-327 (AUPM-327), Curis/Aurigene
    • ENUM005, Enumeral Biomedical
    • JNJ-64158120, Johnson & Johnson
    • LY3321367, Eli Lilly
    • STI-600, Sorrento Therapeutics
    • Sym016, Symphogen A/S
  • Market Forecasts

Chapter 9: CD47/SIRPa

  • Introduction
  • CD47-SIRPa Developmental Therapies
  • Clinical Phase 1/2
    • 5F9, Forty Seven Inc
  • Clinical Programs Phase 1
    • ALX148, ALX Oncology
    • CC-90002, Celgene/InhibRx
    • SRF231, Surface Oncology
    • TTI-621, Trillium
    • TTI-622, Trillium
  • Preclinical Programs
    • OSE-172, Boeringher Ingelheim/ OSE Immunotherapeutics
    • INCAGN2390, Incyte/Agenus
  • Market Forecasts

Chapter 10: Company Profiles

  • ALX ONCOLOGY
  • AGENUS INC.
  • ANAPTYS BIO
  • BEIGENE
  • BIOCAD
  • CSTONE PHARMACEUTICALS
  • CRESCENDO BIOLOGICS LTD.
  • F-STAR BIOTECHNOLOGY
  • FORTY SEVEN, INC.
  • IMMUTEP, LTD.
  • INHIBRX
  • MACROGENICS, INC.
  • OSE IMMUNOTHERAPEUTIC
  • REGENERON PHARMACEUTICALS, INC.
  • SEATTLE GENETICS, INC.
  • SORRENTO THERAPEUTICS, INC.
  • SHANGHAI CELL THERAPY
  • SYMPHOGEN A/S
  • SURFACE ONCOLOGY
  • TESARO, INC.
  • TRILLIUM THERAPEUTICS
  • XENCOR

Chapter 11: Appendix A: List of Abbreviations

Chapter 12: Appendix B: Glossary of Terms

Chapter 13: Appendix C: Sources